

## A

- A $\beta$ , *see* Amyloid  $\beta$ -protein
- Acute-phase reactants, inflammatory markers in brain, 177
- AD, *see* Alzheimer's disease
- Adhesion molecules, inflammatory markers in brain, 186, 187
- Alzheimer's disease (AD), *see also* Familial Alzheimer's disease
- diagnosis, 246, 248
  - glucose metabolism role, 93–96, 110
  - incidence in twins, 225
  - inflammatory processes, 124, 171–174, 188, 189
  - neuropathological stages, 201, 202, 220
  - neuroprotective drugs, 129, 130
  - pathogenesis time, 189
  - pathological hallmarks, 145, 169, 219, 239
  - prevalence, 145, 239, 259
  - vascular alteration, 121, 122
- Amyloid  $\beta$ -protein (A $\beta$ ),
- aggregation, 74, 111, 112, 146, 151, 159
  - antioxidant protection, 159, 161
  - apolipoprotein E, role in deposition,
    - clearance effects, 27, 28
    - insoluble aggregate formation, 28, 29
    - production effects, 29
  - apoptosis in neurons,
    - assay, 74, 75, 81, 82, 84
    - induction, 63, 64, 74, 75, 77, 85
    - mechanism, 77–80
    - receptor crosslinking role, 78–80
  - astrocyte effects, 115, 116
  - ATPase inhibition, 114, 115
  - calcium influx role, 109, 115, 158
  - cerebrospinal fluid concentration, 226, 227
  - complement activation, 184, 185
  - conformation,
    - effects on activity, 73, 75–77, 85, 111–113, 150
    - oxidation effects, 150
  - discovery, 73
  - endothelial cell effects, 116
  - free radical production, 112–115, 147–149, 151–153, 162
  - gene, *see* Amyloid  $\beta$ -protein precursor gene
  - lipid oxidation, 154, 155, 157
  - methionine oxidation, 149, 150
  - microglia effects, 116
  - neurite outgrowth stimulation, 73, 74
  - neurotoxicity, 63, 64, 73, 74, 76, 80, 81, 146
  - overproduction in sporadic Alzheimer's disease,
    - evidence, 45, 46
    - molecular mechanisms, 48–50, 52–54
    - rate-limiting step in production, 47
  - oxidation of enzymes, 149, 158, 159
  - pH effects on aggregation, 112, 231, 232
  - potassium channel effects,
    - artificial lipid bilayer studies, 245
    - function, 244
    - membrane conductance, 245, 246
  - processing, 2, 4, 12, 46–48, 52, 116
  - production in Down's syndrome, 1, 45, 46
  - receptor binding, 76
  - signal transduction disruption, 115
  - synaptosomal membrane protein oxidation, 155–157
  - truncation effects on toxicity, 76, 112, 151, 227
  - vascular alterations and deposition, 121, 122
  - zinc,
    - binding, 228
    - effects on solubility, 225, 227–230
    - iodination effects on binding, 229
    - protection from proteolysis, 229
- Amyloid  $\beta$ -protein precursor (APP),
- biological functions, 3, 226
  - conservation between species, 3
  - domains, 116
  - gene,
    - expression in tissues, 2, 3
    - locus, 111
    - mutations and Alzheimer's disease, 1, 2, 5, 6, 21, 46, 47, 53
    - structure, 2
    - transcription factors, 2, 3
  - intracellular trafficking, 4, 5
  - ion current effects, 117, 119, 120
  - kunitz protease inhibitor domain and plaque formation, 39, 41, 116, 225
  - LDL receptor-related protein binding, 5, 12, 13
  - messenger RNA replication,
    - antisense RNA-mediated RNA-dependent synthesis, 48, 49, 52

- hypothesis testing, 52, 53
  - self-priming synthesis, 49, 50, 52
  - neuroprotection, 117, 120, 123, 124, 126, 127
  - processing, 2, 4, 12, 46–48, 52, 116, 226, 227
  - $\alpha$ -secretase cleavage, 47
  - secreted forms, 116, 117, 119, 120, 225
  - transgenic mice,
    - Alzheimer's disease models, 112
    - behavior measurement, 40
    - expression,
      - levels, 41
      - sites, 41
    - host strain and outcome measures, 40, 41
    - humanization of genes, 53
    - hypothesis testing, 41–43
    - protein isoforms and phenotypes, 39, 40
    - translation initiation site, 48
    - zinc binding, 226
  - Antioxidants, amyloid  $\beta$ -protein protection, 159, 161
  - ApoE, *see* Apolipoprotein E
  - Apolipoprotein E (ApoE),
    - amyloid  $\beta$ -protein deposition role,
      - clearance effects, 27, 28
      - insoluble aggregate formation, 28, 29
      - production effects, 29
    - ApoE- $\epsilon$ 4 variant,
      - atherosclerosis association, 122
      - effect on amyloid deposition, 12
      - effect on other neurodegenerative diseases, 26
      - penetrance, 21
    - central nervous system functions, 23–25
    - dimerization, 22, 23
    - isoforms, 21
    - lipoprotein binding, 22–24
    - models of involvement in Alzheimer's disease, 25
    - neurite outgrowth role, 26
    - neurofibrillary tangle development role, 26
    - potentiation of amyloid  $\beta$ -protein precursor neuroprotection, 123, 124
    - receptors,
      - binding, 22, 25
      - expression in central nervous system, 25
      - types, 23
    - structure, 21
    - synaptic regeneration role, 25, 26
    - synthesis, 123
  - Apoptosis,
    - activation signals, 58, 77
    - Alzheimer's disease,
      - amyloid  $\beta$ -protein, induction of
        - apoptosis, 63, 64, 74, 75, 85
      - assay, 81, 82, 84
      - DNA repair, 85
      - signals of apoptosis, 62, 63
      - signs of apoptosis, 63
    - commitment, 58, 59
    - defined, 57, 81, 103
    - elimination of cells, 59
    - inhibitor proteins, 12, 58, 59
    - initiation, 58
    - neurons,
      - apoptotic signals, 60
      - cell culture, 59, 60
      - commitment and inhibitors, 61, 64, 84
      - Concanavalin A model, 78–80, 85
      - detection of apoptosis in brain, 62
      - elimination, 61
      - execution, 61
      - initiation genes, 60, 61, 83, 84
      - receptor crosslinking role, 78–80
    - proteases, 59
    - senescent cells, 57
    - stages, 57–59
    - T-cells, 77, 78
  - APP, *see* Amyloid  $\beta$ -protein precursor
  - Astrocyte,
    - amyloid  $\beta$ -protein effects, 115, 116
    - neuroprotection, 128
    - plaque composition, 128, 171
- B**
- Basic fibroblast growth factor (bFGF),
    - neuroprotective signaling, 124, 125
  - BDNF, *see* Brain-derived neurotrophic factor
  - bFGF, *see* Basic fibroblast growth factor
  - Binswanger's disease, *see* Vascular dementia
  - Brain-derived neurotrophic factor (BDNF),
    - neuroprotective signaling, 124, 125
- C**
- Calcium,
    - amyloid  $\beta$ -protein and influx, 109, 115, 244
    - binding protein expression in brain, 107, 109
    - channels, 104
    - concentration in neurons, 104
    - dyshomeostasis and Alzheimer's disease, 107–110
    - free radical induction, 106
    - homeostasis in neurons, 104, 106
    - intracellular release in Alzheimer's disease, 241, 248
    - neurotoxicity, 108

- Carbamazepine, neuroprotection mechanism, 129, 130
- Ceramide, neuroprotection mechanism, 129, 130
- Cerebral infarction, *see* Vascular dementia
- Chromakalim, neuroprotection mechanism, 129, 130
- Complement,
  - cascade, 183, 184
  - Clq binding to amyloid  $\beta$ -protein, 184, 185
  - defense proteins, 186
  - distribution in brain, 184
  - inflammatory markers in brain, 184–186
  - membrane attack complex, 184
  - receptors and upregulation in dementia, 187
- Complex IV, activity in Alzheimer's disease, 94
- Concanavalin A, apoptosis induction in neurons, 78–80, 85
- Cp20,
  - alterations in Alzheimer's disease fibroblasts, 247
  - amyloid  $\beta$ -protein effects, 244
  - deficit in Alzheimer's disease, 244
- Cytochalasin D, neuroprotection mechanism, 129, 130
- D**
- Delirium, cerebral glucose metabolism dependence, 91
- Dementia, *see also* Prion disease; Vascular dementia
  - defined, 271
  - etiological groups, 271
- Diazoxide, neuroprotection mechanism, 129, 130
- Dihydrolipoyl succinyltransferase (DLST), mutations in late-onset Alzheimer's disease, 96
- DLST, *see* Dihydrolipoyl succinyltransferase
- Down's syndrome,
  - $\beta$ -amyloid production, 1, 45, 46, 172, 173
  - apolipoprotein E genotype, 27
  - neuron apoptosis, 111
  - oxyradical metabolism, 111
- E**
- Eicosanoids, inflammatory markers in brain, 187
- Electron paramagnetic resonance (EPR),
  - amyloid  $\beta$ -protein studies, 112, 113, 146–148
  - lipid oxidation assay, 154, 155
  - sensitivity, 147
  - spin trapping, 146–148
- Epilepsy, Alzheimer's disease risk factor, 173
- EPR, *see* Electron paramagnetic resonance
- Estrogen, Alzheimer's disease protection, 122
- Excitotoxic injury, glucose metabolism effects, 98
- F**
- FAD, *see* Familial Alzheimer's disease
- Familial Alzheimer's disease (FAD),
  - age of onset, 1
  - genes,
    - amyloid  $\beta$ -protein precursor gene mutations, 1, 2, 5, 6, 21, 46, 47, 53
  - loci, 1
  - presenelins, 2, 8–10, 21
  - STM2, 120, 121
- Fluorescence spectroscopy, free radical assay, 156, 157
- Free radicals,
  - amyloid  $\beta$ -protein and radical production, 112–115, 147–149, 151–153
  - calcium induction, 106
  - cellular sources, 106
  - glucose metabolism and scavenging, 98
  - metabolism in Down's syndrome, 111
  - metabolism in neurons, 106, 107
  - role in Alzheimer's disease, 153, 154, 162
- G**
- GAPDH, *see* Glyceraldehyde-3-phosphate dehydrogenase
- Glucocorticoids, Alzheimer's disease role, 122
- Glucose metabolism,
  - cellular homeostasis maintenance, 97, 99
  - delirium effects, 91
  - excitotoxicity effects, 98
  - free radical scavenging role, 98
  - role in neurodegenerative diseases, 93–96, 110
- Glutamate, neurotoxicity, 106, 107
- Glutamine synthase (GS),
  - Alzheimer's disease marker, 158
  - oxidation by amyloid  $\beta$ -protein, 158, 159
- Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), polyglutamine binding, 92, 96
- GS, *see* Glutamine synthase
- H**
- HD, *see* Huntington's disease
- Head trauma, risk factor for Alzheimer's disease, 172, 173
- Huntington's disease (HD), glucose metabolism role, 93–96
- I**
- IGF-1, *see* Insulin-like growth factor-1
- IL-1, *see* Interleukin-1

- Inflammation,  
 Alzheimer's disease role, 124, 171–174,  
 188–190  
 markers in brain, 178–183  
 therapy and Alzheimer's disease prevention,  
 174, 188
- Insulin-like growth factor-1 (IGF-1),  
 neuroprotective signaling, 124, 125
- Interleukin-1 (IL-1),  
 expression in Down's syndrome, 173  
 inflammatory marker in brain, 183  
 plaque evolution role, 171, 172
- Ischemia, *see* Vascular dementia
- K**
- $\alpha$ -Ketoglutarate dehydrogenase, activity in  
 Alzheimer's disease, 94–96
- L**
- LDL receptor-related protein (LRP), amyloid  $\beta$ -  
 protein precursor binding, 5, 12, 13
- Leukoaraiosis, *see* Vascular dementia
- M**
- Major histocompatibility complex (MHC),  
 inflammatory markers in brain, 177
- Memory,  
 Cp20 role, 244  
 molecular mechanisms, 240
- MHC, *see* Major histocompatibility complex
- Microglia,  
 amyloid  $\beta$ -protein effects, 116  
 neurotoxic effects, 128  
 plaque composition, 128, 171
- N**
- Nerve growth factor (NGF), neuroprotective  
 signaling, 124, 125
- Neurofibrillary tangle (NFT), *see also* Paired  
 helical filament  
 amyloid  $\beta$ -protein role in formation, 109  
 animal models, 211  
 apolipoprotein E role in development, 26  
 calcium content, 108  
 dementia role, 200  
 distribution in brain, 219, 220  
 filaments, 199
- NGF, *see* Nerve growth factor
- Nonsteroidal anti-inflammatory drugs  
 (NSAIDs), prevention of Alzheimer's  
 disease, 174
- NSAIDs, *see* Nonsteroidal anti-inflammatory  
 drugs
- P**
- Paired helical filament (PHF),  
 assembly, 207, 210  
 composition, 199, 206–209  
 structure, 202, 203
- Phenytoin, neuroprotection mechanism, 129,  
 130
- PHF, *see* Paired helical filament
- Pick disease,  
 associated syndromes, 260  
 ballooned neurons, 262  
 brain morphology, 263, 264  
 classification, 253, 256, 258  
 clinical course, 259, 260  
 diagnosis, 253, 256, 258, 259, 264, 265  
 epidemiology, 259  
 neuropathological hallmarks, 258, 259, 261–  
 265  
 Pick body characteristics, 261, 262, 265  
 status spongiosus, 262, 263  
 symptoms, 253, 258, 260
- PKC, *see* Protein kinase C
- Plaque, *see* Senile plaque
- Plasmin, inflammatory marker in brain, 188
- PN-1, *see* Protease nexin-1
- Potassium channel,  
 activation by amyloid  $\beta$ -protein precursor,  
 117, 119, 120  
 alterations in Alzheimer's disease  
 fibroblasts, 240, 241, 247  
 amyloid  $\beta$ -protein effects,  
 artificial lipid bilayer studies, 245  
 function, 244  
 membrane conductance, 245, 246  
 diagnostic value, 246  
 intracellular calcium release in Alzheimer's  
 disease, 241, 248  
 therapeutic potential in Alzheimer's disease,  
 246
- Presenelin 1 (PS1),  
 biological functions, 10–12  
 gene,  
 expression in tissues, 7, 8  
 locus, 6  
 structure, 8  
 transcripts, 7  
 homology with other proteins, 10, 11  
 mutations and Alzheimer's disease, 2, 8–10,  
 21, 121  
 processing, 10  
 structure, 6  
 subcellular localization, 10, 11
- Presenelin 2 (PS2),  
 apoptosis inhibition, 12  
 biological functions, 10–12  
 gene,  
 expression in tissues, 7, 8

- locus, 6
  - transcripts, 7
  - homology with other proteins, 10, 11
  - mutations and Alzheimer's disease, 2, 8–10, 21
  - processing, 10
  - structure, 6
  - subcellular localization, 10, 11
  - Prion disease,
    - dementia association,
      - CJD phenotype, 296–298
      - disease classification, 295, 297
      - FFI phenotype, 298, 299
      - GSS phenotype, 299, 300
      - heterogenous phenotype, 300
      - molecular mechanisms, 300–303
    - pathogenesis, 293
    - phenotypes, 293–296, 303
  - Programmed cell death, *see* Apoptosis
  - Protease nexin-1 (PN-1),
    - neuroprotective signaling, 127, 128
    - thrombin inhibition, 127
  - Protein kinase C (PKC), effect on potassium channels, 240, 248
  - PS1, *see* Presenelin 1
  - PS2, *see* Presenelin 2
  - Pyruvate dehydrogenase, activity in Alzheimer's disease, 94–96
- S**
- S100 $\beta$ , plaque evolution role, 171, 172
  - Senile plaque (SP),
    - composition, 128, 169, 171
    - distribution in brain, 219, 220
    - evolution, 169, 170
    - oxidative stress, 145, 146, 161
  - SF, *see* Straight filament
  - SP, *see* Senile plaque
  - Spinocerebellar ataxia, glucose metabolism role, 93–96
  - Staurosporine, neuroprotection mechanism, 129, 130
  - STM2,
    - calcium homeostasis role, 120, 132
    - mutation and Alzheimer's disease, 120, 121
    - structure, 131
  - Straight filament (SF),
    - composition, 199
    - structure, 202, 203
  - Stroke, *see* Vascular dementia
- T**
- $\tau$ ,
    - apolipoprotein E interactions, 27, 210
    - distribution, 203
    - functions, 205, 206
    - isoforms, 203, 208
    - microtubule-binding domains, 203, 205
    - phosphorylation,
      - defects in Alzheimer's disease, 209
      - inhibition of microtubule binding, 206
      - kinases, 204, 209
      - phosphatases, 204, 205, 209
      - sites, 203, 204, 208
    - proteolysis, 206, 207
    - transgenic mice, 210, 211
  - TGF $\beta$ , *see* Transforming growth factor- $\beta$
  - Thrombin,
    - inflammatory marker in brain, 187
    - neurotoxic effects, 127, 128, 159
  - TNF, *see* Tumor necrosis factor
  - Transforming growth factor- $\beta$  (TGF $\beta$ ),
    - neuroprotective signaling, 124, 125
  - Transgenic mice,
    - amyloid  $\beta$ -protein precursor,
      - Alzheimer's disease models, 112
      - behavior measurement, 40
      - expression,
        - levels, 41
        - sites, 41
      - host strain and outcome measures, 40, 41
      - humanization of genes, 53
      - hypothesis testing, 41–43
      - protein isoforms and phenotypes, 39, 40
    - knockout mice and neurological diseases, 92
    - $\tau$  phosphorylation models, 210, 211
  - Tumor necrosis factor (TNF),
    - inflammatory marker in brain, 183
    - neuroprotective signaling, 125, 126
    - receptors, 126
- V**
- Vascular dementia,
    - animal models, 280, 281
    - Binswanger's disease,
      - diagnosis, 275, 276
      - prevalence, 276
    - blood–brain barrier dysfunctions, 277
    - cerebral infarction,
      - dementia prevalence, 273
      - factors affecting dementia, 274, 275
    - cerebrovascular autoregulation dysfunction, 277, 278
    - clinical models,
      - hereditary vascular dementia, 280
      - mixed dementia, 279, 280
      - multi-infarct dementia, 278
      - strategic-infarct dementia, 279
      - subcortical dementia, 279
    - diagnosis,
      - comparison of criteria, 285

- DSM-III-R criteria, 281
  - functional neuroimaging, 287
  - Hachinski's ischemic score, 281
  - ICD-10 criteria, 282, 283
  - modified ischemic score, 281
  - NINDS-AIREN criteria, 284, 285
  - pathology, 272
  - State of California Alzheimer's Disease Diagnostic and Treatment Centers criteria, 283, 284
  - etiology, 272
  - heredity, 288
  - historical overview, 271, 272
  - intracranial hemorrhage as cause, 278
  - leukoaraiosis,
    - dementia prevalence, 276
    - diagnosis, 276, 277
    - treatment, 277
  - neuroprotection mechanisms, 288
  - prevention, 272, 273
  - treatment and prevention,
    - brain-at-risk stage, 286, 287
    - dementia stage, 287
    - feasibility, 271
    - predementia stage, 287
    - vascular cognitive impairment, 286, 287
  - Volga German gene, *see* STM2
- Z**
- Zinc,
    - amyloid  $\beta$ -protein binding,
      - effects on solubility, 225, 227–230
      - iodination effects on binding, 229
      - protection from proteolysis, 229
      - site, 228
    - hippocampal concentration, 230, 231
    - metabolism in Alzheimer's disease, 230, 231
    - neurotoxicity, 230, 231
    - uptake in brain, 230